Achieve Life Sciences Stock (NASDAQ:ACHV)

Forecast Ownership Financials Chart Transcripts

Previous Close

$5.75

52W Range

$2.00 - $6.16

50D Avg

$4.58

200D Avg

$4.27

Market Cap

$566.68M

Avg Vol (3M)

$1.40M

Beta

2.26

Div Yield

ACHV Company Profile

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 12, 1995

Website

ACHV Performance

ACHV Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-54.88M	$-39.07M	$-27.25M
Net Income	$-54.65M	$-39.83M	$-29.82M
EBITDA	$-54.65M	$-37.42M	$-26.73M
Basic EPS	$-1.25	$-1.24	$-1.50
Diluted EPS	$-1.25	$-1.24	$-1.50

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 24, 26 | 8:30 AM

Q3 25Nov 06, 25 | 8:30 AM

Q2 25Aug 08, 25 | 8:30 AM

Peer Comparison

Ticker	Company
ARCT	Arcturus Therapeutics Holdings Inc.
CAPR	Capricor Therapeutics, Inc.
ALLO	Allogene Therapeutics, Inc.
HUMA	Humacyte, Inc.
AVIR	Atea Pharmaceuticals, Inc.
VNDA	Vanda Pharmaceuticals Inc.
SGMT	Sagimet Biosciences Inc.
VYGR	Voyager Therapeutics, Inc.
TRDA	Entrada Therapeutics, Inc.
IMRX	Immuneering Corporation